Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 20/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 14/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175592 | 0.86 | CYP11B2 (0.76) | CYP11B2CYP11B1HTR2B | |
| SCHEMBL10176201 | 0.86 | CYP11B2 (0.64) | CYP11B2CYP11B1CYP19A1ADRA2BADRB1 | |
| SCHEMBL17896716 | 0.85 | CYP11B2 (0.59) | CYP11B2CYP11B1CYP19A1ADRA2B | |
| SCHEMBL17896710 | 0.85 | CYP11B2 (0.62) | CYP11B2CYP11B1CYP19A1ADRA2BADRB1 | |
| SCHEMBL10175465 | 0.84 | CYP11B2 (0.61) | CYP11B2CYP11B1CYP19A1ADRA2BADRB1 | |
| SCHEMBL17896709 | 0.84 | CYP11B2 (0.61) | CYP11B2CYP11B1CYP19A1ADRA2BADRB1 | |
| SCHEMBL10175450 | 0.83 | CYP11B2 (0.60) | CYP11B2CYP11B1CYP19A1ADRA2BADRB1 | |
| SCHEMBL10175117 | 0.81 | CYP11B2 (0.67) | CYP11B2CYP11B1CYP19A1ADRA2B | |
| SCHEMBL17896712 | 0.81 | CYP11B2 (0.67) | CYP11B2CYP11B1CYP19A1ADRA2BADRB1 | |
| SCHEMBL10175441 | 0.78 | CYP11B2 (0.62) | CYP11B2CYP11B1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562306-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2025-02-26 | — | — | EP | claimed |
| US-20220009907-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2022-01-13 | — | — | US | claimed |
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2020-12-17 | — | — | US | claimed |
| EP-3562306-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Selenity Therapeutics (Bermuda), Ltd. (BM) | 2019-11-06 | — | — | EP | claimed |
| WO-2018125799-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | claimed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | claimed |
| EP-3562306-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2025-02-26 | — | — | EP | disclosed |
| US-11919883-B2 | Metalloenzyme inhibitor compounds | JI XING PHARMACEUTICALS HONG KONG LIMITED (HK) | 2024-03-05 | — | — | US | disclosed |
| US-20220009907-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2022-01-13 | — | — | US | disclosed |
| US-20220009907-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2022-01-13 | — | — | US | disclosed |
| US-11136309-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136309-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2020-12-17 | — | — | US | disclosed |
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2020-12-17 | — | — | US | disclosed |
| EP-3562306-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Selenity Therapeutics (Bermuda), Ltd. (BM) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018125799-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| WO-2018125799-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | CYP11B2 405/4885CYP11B1 370/4885CYP19A1 1309/4885 |
| US-20220009907-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | CYP11B2 405/4885CYP11B1 370/4885CYP19A1 1309/4885 |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | CYP11B2 405/4885CYP11B1 370/4885CYP19A1 1309/4885 |
| US-11136309-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | CYP11B2 405/4885CYP11B1 370/4885CYP19A1 1309/4885 |
| US-11919883-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | CYP11B2 405/4885CYP11B1 370/4885CYP19A1 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.